Expression pattern of p‑Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma

Liu,Nannan; Qi,Dongxue; Jiang,Jing; Zhang,Jihong; Yu,Chunyan

doi:10.3892/ol.2020.11297

Expression pattern of p‑Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma

Authors:
- Nannan Liu
- Dongxue Qi
- Jing Jiang
- Jihong Zhang
- Chunyan Yu
View Affiliations

Affiliations: Department of Pathology, Medicine College of Beihua University, Jilin 132013, P.R. China, Department of Pathology, Lianyungang First People's Hospital, Lianyungang, Jiangsu 222000, P.R. China, Department of Pathology, Affiliated Hospital of Beihua University, Jilin 132011, P.R. China
Published online on: January 13, 2020 https://doi.org/10.3892/ol.2020.11297
Pages: 1789-1798
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study examined SMAD family member 4 (Smad4), SMAD family member 2 (Smad2) and phosphorylated (p‑)Smad2 expression in biopsy specimens from patients with invasive breast ductal carcinoma, in order to assess their abilities as prognostic markers. A total of 126 tissue samples were selected, and the expression of Smad2, p‑Smad2 and Smad4 in carcinoma tissues was detected by immunostaining, and the association between protein expression and clinicopathological variables was analyzed. Smad4 expression was negatively correlated with human epidermal growth factor receptor 2 in carcinoma tissues, and Smad4 expression was consistent with that of p‑Smad2. Although multivariate analysis revealed that Smad2, p‑Smad2 and Smad4 were not independent predictors, Kaplan‑Meier curves demonstrated that Smad4 positivity was correlated with a longer overall survival (OS) and progression‑free survival (PFS) time. However, upon analysis of combined markers, there was a significant difference between the p‑Smad2/Smad4 co‑positive and co‑negative patients; the latter tended to exhibit a shorter OS and PFS time, and multivariate analysis revealed that the combined expression of p‑Smad2 and Smad4 may be used as an independent prognostic factor. These results suggested that the assessment of p‑Smad2 and Smad4 protein expression in breast ductal carcinoma biopsy specimens may provide additional prognostic information.

View Figures

View References

1	Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI
2	Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Pérez JE, Leone J and Leone JP: Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 161:537–548. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen HS, Bai MH, Zhang T, Li GD and Liu M: Ellagic acid induces cell cycle arrest and apoptosis through TGF-β/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 46:1730–1738. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lo PK, Zhang Y, Yao Y, Wolfson B, Yu J, Han SY, Duru N and Zhou Q: Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGF β signaling. J Biol Chem. 292:11466–11484. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yang KM, Kim W, Bae E, Gim J, Weist BM, Jung Y, Hyun JS, Hernandez JB, Leem SH, Park T, et al: DRAK2 participates in a negative feedback loop to control TGF-β/Smads signaling by binding to type I TGF-β receptor. Cell Rep. 2:1286–1299. 2012. View Article : Google Scholar : PubMed/NCBI
6	Massagué J: TGF β signaling in context. Nat Rev Mol Cell Biol. 13:616–630. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F and Fändrich F: Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: Control by Rac1. Mol Cancer. 10:672011. View Article : Google Scholar : PubMed/NCBI
8	Wu Y, Li Q, Zhou X, Yu J, Mu Y, Munker S, Xu C, Shen Z, Müllenbach R, Liu Y, et al: Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer. PLoS One. 7:e356842012. View Article : Google Scholar : PubMed/NCBI
9	Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G and Ten Dijke P: Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 29:1351–1361. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT and Fiocca R: Reduced expression of SMAD4 is associated with poor survival in colon cancer. Clin Cancer Res. 22:3037–3047. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A and Kodera Y: SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas. 44:660–664. 2015. View Article : Google Scholar : PubMed/NCBI
12	Stuelten CH, Buck MB, Dippon J, Roberts AB, Fritz P and Knabbe C: Smad4-Expression is decreased in breast cancer tissues: A retrospective study. BMC Cancer. 6:252006. View Article : Google Scholar : PubMed/NCBI
13	Li Q, Wu L, Oelschlager DK, Wan M, Stockard CR, Grizzle WE, Wang N, Chen H, Sun Y and Cao X: Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells. J Biol Chem. 280:27022–27028. 2005. View Article : Google Scholar : PubMed/NCBI
14	So JY, Lee HJ, Kramata P, Minden A and Suh N: Differential expression of key signaling proteins in MCF10 cell lines, a human breast cancer progression model. Mol Cell Pharmacol. 4:31–40. 2012.PubMed/NCBI
15	Barroso-Sousa R and Metzger-Filho O: Differences between invasive lobular and invasive ductal carcinoma of the breast: Results and therapeutic implications. Ther Adv Med Oncol. 8:261–266. 2016. View Article : Google Scholar : PubMed/NCBI
16	Taubert H, Heidenreich C, Holzhausen HJ, Schulz A, Bache M, Kappler M, Eckert AW, Würl P, Melcher I, Hauptmann K, et al: Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 10:652010. View Article : Google Scholar : PubMed/NCBI
17	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
18	Luo K: Signaling cross talk between TGF-β/Smad and other signaling pathways. Cold Spring Harb Perspect Biol. 9:a0221372017. View Article : Google Scholar : PubMed/NCBI
19	Kretzschmar M: Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res. 2:107–115. 2000. View Article : Google Scholar : PubMed/NCBI
20	Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, Wang H, Chatterjee D, Fleming JB, Li M, et al: Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res. 19:549–559. 2013. View Article : Google Scholar : PubMed/NCBI
21	Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M and Zappa M: Female breast cancer status according to ER, PR and HER2 expression: A population based analysis. Pathol Oncol Res. 17:753–758. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen L, Zhong J, Liu JH, Liao DF, Shen YY, Zhong XL, Xiao X, Ding WJ, Peng XD, Xiong W and Zu XY: Pokemon inhibits transforming growth factor β-Smad4-related cell proliferation arrest in breast cancer through specificity protein 1. J Breast Cancer. 22:15–28. 2019. View Article : Google Scholar : PubMed/NCBI
23	Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, Zhang HZ, Wu J, Liu L, Song J, et al: CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling. J Clin Invest. 127:1725–1740. 2017. View Article : Google Scholar : PubMed/NCBI
24	Yang J, Wahdan-Alaswad R and Danielpour D: Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. Cancer Res. 69:2185–2190. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hoot KE, Lighthall J, Han G, Lu SL, Li A, Ju W, Kulesz-Martin M, Bottinger E and Wang XJ: Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest. 118:2722–2732. 2008.PubMed/NCBI
26	Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K and Kato M: Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res. 62:5955–5961. 2002.PubMed/NCBI
27	Zhao M, Mishra L and Deng CX: The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 14:111–123. 2018. View Article : Google Scholar : PubMed/NCBI
28	Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, et al: Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 147:196–208. 2014. View Article : Google Scholar : PubMed/NCBI
29	Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al: SMAD4-Dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wu KJ, Zhu GF, Zhang D, Zeng J, Wang XY, Xue Y, Zhang LL and He DL: Identification of TGF-beta/Smads pathway in human prostate cancer cell lines and its significance. Zhonghua Nan Ke Xue. 15:920–924. 2009.(In Chinese). PubMed/NCBI
31	Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, DuPont NC, Clark K, Lele S and Liu S: Expression and clinical significance of the transforming growth factor-β signalling pathway in endometrial cancer. Histopathology. 59:63–72. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao WH, Liu XY, Wang Y, Yang ZC, Xu HM and Wang HB: Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Oncol Rep. 29:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
33	Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG and Reiss M: Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res. 62:497–505. 2002.PubMed/NCBI
34	Won KY, Kim YW and Park YK: Expression of smad and its signalling cascade in osteosarcoma. Pathology. 42:242–247. 2010. View Article : Google Scholar : PubMed/NCBI